The role of eosinophils in chronic spontaneous urticaria - 08/06/20
Abstract |
Chronic spontaneous urticaria (CSU) is considered to be primarily a mast cell–driven disease. However, recent evidence suggests that eosinophils may also have an axial role in symptomology. Histologic studies have demonstrated the presence of both eosinophils and eosinophil granules, indicative of activation, in CSU lesions. Although many allergic and inflammatory conditions are associated with a peripheral blood eosinophilia, the converse appears to be the case in CSU, with a peripheral blood eosinopenia being observed in many patients. Possible mechanisms include the depletion of blood eosinophils by recruitment into the skin during active disease and immunologic destruction in the blood. We also address in some detail the interactions between eosinophils and mast cells, particularly the cytokine cross-talk of these cells and mediator release possibly leading to clinical symptoms. Also, activation by eosinophil proteins of the coagulation pathway leads to the generation of thrombin and increased mast cell degranulation. Finally, treatments aimed at reducing eosinophil accumulation and activation, such as the anti–IL-5 antibodies mepolizumab, reslizumab, and benralizumab, have been reported to reduce CSU symptoms. Clearly, a new picture of an important role of eosinophils in the pathogenesis of CSU is emerging.
Il testo completo di questo articolo è disponibile in PDF.Key words : Urticaria chronic spontaneous urticaria, mast cell, eosinophil
Abbreviations used : CCL11, CCL24, CLC, CSU, ECP, EDN, EPO, MBP, MCP3, PAF, PAR, Siglec, VEGF
Mappa
P. Kolkhir was supported by a GA2LEN fellowship. This project benefitted from the support of the GA2LEN network of Urticaria Centers of Reference and Excellence (www.ga2len-ucare.com) and the Russian Academic Excellence Project 5-100. |
|
Disclosure of potential conflict of interest: S. Altrichter is or was recently a speaker and/or advisor for and/or has received research funding from Allakos, AstraZeneca, Moxie, and Sanofi. P. Kolkhir is or was recently a speaker for Novartis and Roche. M. Maurer is or was recently a speaker and/or advisor for and/or has received research funding from Allakos, Aralez, AstraZeneca, FAES, Genentech, Menarini, Novartis, Leo Pharma, Lilly, Moxie, MSD, Roche, Sanofi, UCB, and Uriach. M. Church has been a speaker or consultant for Almirall, FAES Pharma, Menarini, Moxie, MSD, Novartis, UCB Pharma, Sanofi-Aventis, and Uriach. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 145 - N° 6
P. 1510-1516 - Giugno 2020 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?